Corporate History

2005
  • October 1, Sumitomo Dainippon Pharma created.
2006
  • AmBisome® (therapeutic agent for systemic fungal infection) launched in Japan.
2007
  • REPLAGAL® (therapeutic agent for Anderson-Fabry disease) launched in Japan.
  • The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd.
  • Draw up the Mid-term Business Plan (FY2007-FY2009).
2008
  • LONASEN® (atypical antipsychotic) launched in Japan.
  • AVAPRO® (therapeutic agent for hypertension) launched in Japan.
2009
  • TRERIEF® (Parkinson's disease drug) launched in Japan.
  • A holding company (Dainippon Sumitomo Pharma America Holdings, Inc.) established in the U.S.
  • Acquired Sepracor Inc. (currently, Sunovion Pharmaceuticals Inc.), Sepracor (currently, Sunovion Pharmaceuticals Inc.) became a wholly owned subsidiary of the U.S. holdings company.
    Sunovion Pharmaceuticals Inc.
    Sunovion Pharmaceuticals Inc.
2010
  • MIRIPLA® (therapeutic agent for hepatocellular carcinoma) launched in Japan.
  • Draw up the Second Mid-term Business Plan (FY2010-FY2012).
  • Sepracor Inc. (currently, Sunovion Pharmaceuticals Inc.) and Dainippon Sumitomo Pharma America, Inc. merged.
  • METGLUCO® (biguanide oral hypoglycemic) launched in Japan.
  • Growth hormone business transferred.
  • The Animal Health Products business split off and DS Pharma Animal Health Co., Ltd. established.
  • The Food & Speciality Products business integrated into its subsidiary Gokyo Trading Co., Ltd. and corporate name changed to DSP Gokyo Food & Chemical Co., Ltd.
  • Sepracor Inc. changed its company name to Sunovion Pharmaceuticals Inc.
2011
  • LATUDA® (atypical antipsychotic) launched in Japan in the U.S. by Sunovion Pharmaceuticals Inc.
  • SUREPOST® (rapid-acting insulin secretagogue) launched in Japan.
2012
  • Acquired Boston Biomedical, Inc.
    Boston Biomedical, Inc.
    Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals Inc. Acquired Elevation Pharmaceuticals, Inc. (currently, SRD).
  • AIMIX® (therapeutic agent for hypertension) launched in Japan.
2013
  • A Subsidiary (Sunovion Pharmaceuticals Asia Pacific Pte Ltd.) established in Singapore.
  • Draw up the Third Mid-term Business Plan (FY2013-FY2017).
  • Dainippon Sumitomo Pharma Europe Ltd. changed its company name to Sunovion Pharmaceuticals Europe Ltd.
  • An anti-cancer drugs sales subsidiary company (Boston Biomedical Pharma,Inc.) established in the U.S.
2014
  • Joint venture company (Sighregen Co., Ltd.) established.
  • Kobe Regenerative & Cellular Medicine Center (currently, Regenerative & Cellular Medicine Kobe Center) opened.
    Kobe Regenerative & Cellular Medicine Center
    Regenerative & Cellular Medicine Kobe Center
  • APTIOM® (antiepileptic) launched in the U.S. by Sunovion Pharmaceuticals Inc.
  • LATUDA® (atypical antipsychotic) launched in the U.K. by Sunovion Pharmaceuticals Europe Ltd.
2015
  • Started promotion for the indication "pruritus in chronic liver disease patients " of REMITCH®.
  • Trulicity® (GLP-1 receptor agonist) launched in Japan.
2016
  • Sunovion Pharmaceuticals Inc. acquired Cynapsus Therapeutics Inc., a Canadian company (currently, Sunovion CNS Development Canada ULC)
  • A Subsidiary for Promotion of Authorized Generics and others (DS Pharma Promo Co., Ltd.) established.
2017
  • Acquired Tolero Pharmaceuticals, Inc.
  • Boston Biomedical Pharma, Inc. integrated into its subsidiary Boston Biomedical, Inc. and corporate name changed to Boston Biomedical, Inc.
  • Dainippon Sumitomo Pharma America Holdings, Inc. changed its company name to Sumitomo Dainippon Pharma America, Inc.
2018
  • LONASEN® (atypical antipsychotic) launched in China by Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
  • Manufacturing Plant for Regenerative Medicine & Cell Therapy (SMaRT) completed.
  • Started promotion for EFFEXOR® SR Capsules.
  • LONHALA® MAGNAIR® (therapeutic agent for COPD) launched in the U.S. by Sunovion Pharmaceuticals Inc.
2019
  • Reoragnized product sites from 4 sites to 2 sites.
  • Succession to the in-vitro diagnostics business of DS Pharma Biomedical Co., Ltd. by a joint company and consolidation with DS Pharma Promo Co., Ltd.
  • Sunovion Pharmaceuticals Asia Pacific Pte. Ltd. changed its corporate name to Sumitomo Pharmaceuticals Asia Pacific Pte.Ltd. and established a subsidiary (Sumitomo Pharmaceuticals (Thailand) Co., Ltd.) in Thailand.
  • Draw up the Mid-term Business Plan 2022 (FY2018-FY2022).
  • RETHIO® (conditioning treatment prior to autologous hematopoietic stem cell transplantation) launched in Japan.
  • Started sales of Equa® and EquMet® (therapeutic agent for type 2 diabates) in Japan.
  • LATUDA® (atypical antipsychotic) launched in China by Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
  • LONASEN® Tape (atypical antipsychotic) launched in Japan.
  • With the signing of a strategic alliance agreement with Roivant Sciences, a U.S. subsidiary Sumitovant Biopharma was established to hold shares of Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences.
2020
  • LATUDA® (atypical antipsychotic) launched in Japan.
  • Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. integrated and corporate name changed to Sumitomo Dainippon Pharma Oncology, Inc.
  • Joint venture company (S-RACMO Co., Ltd.) for CDMO Business in the field of Regenerative Medicine and Cell Therapy established.
  • A subsidiary (Sumitomo Pharmaceuticals Taiwan Co., Ltd.) established in Taiwan.
  • KYNMOBI™ launched in the U.S. by Sunovion Pharmaceuticals Inc.
2021
  • ORGOVYX™ (therapeutic agent for advanced prostate cancer) launched in the U.S. by Myovant Sciences Ltd.
  • Sumitovant Biopharma Ltd. made Urovant Sciences Ltd., a U.S. consolidated subsidiary its wholly-owned subsidiary.
  • GEMTESA® (therapeutic agent for overactive bladder (OAB)) launched in the U.S. by Urovant Sciences Ltd.
  • Transferred shares of Sunovion Pharmaceuticals Europe Ltd.